Neumora Therapeutics (NMRA) Net Income towards Common Stockholders (2022 - 2026)
Neumora Therapeutics (NMRA) recorded Net Income towards Common Stockholders of -$43.08 million in Q2 2026, compared with -$52.73 million a year earlier.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
On a TTM basis, Neumora Therapeutics' Net Income towards Common Stockholders came in at -$212.75 million as of Jun 30, 2026; for FY2025, it came in at -$236.93 million.
- Across earlier years, Net Income towards Common Stockholders came in at -$243.79 million in FY2024, -$235.93 million in FY2023 and -$130.9 million in FY2022.
- The Q2 2026 figure is the highest quarterly Net Income towards Common Stockholders since Q2 2023.
- Per Business Quant, the preceding three quarters came in at -$53.46 million (Q1 2026), -$59.45 million (Q4 2025) and -$56.76 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Neumora Therapeutics | 93.95 Mn | 93.95 Mn | - | -43.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.08 Mn |
| Mar 31, 2026 | -53.46 Mn |
| Dec 31, 2025 | -59.45 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.73 Mn |
| Mar 31, 2025 | -67.99 Mn |
| Dec 31, 2024 | -58.82 Mn |
| Sep 30, 2024 | -72.55 Mn |
| Jun 30, 2024 | -58.70 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.73 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -35.63 Mn |
| Dec 31, 2022 | -28.15 Mn |
| Sep 30, 2022 | -29.34 Mn |
API Access
Neumora Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();